JP2019503348A5 - - Google Patents

Download PDF

Info

Publication number
JP2019503348A5
JP2019503348A5 JP2018530797A JP2018530797A JP2019503348A5 JP 2019503348 A5 JP2019503348 A5 JP 2019503348A5 JP 2018530797 A JP2018530797 A JP 2018530797A JP 2018530797 A JP2018530797 A JP 2018530797A JP 2019503348 A5 JP2019503348 A5 JP 2019503348A5
Authority
JP
Japan
Prior art keywords
peg
amino acid
molecule
kda
acid residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018530797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019503348A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/067042 external-priority patent/WO2017112528A2/en
Publication of JP2019503348A publication Critical patent/JP2019503348A/ja
Publication of JP2019503348A5 publication Critical patent/JP2019503348A5/ja
Withdrawn legal-status Critical Current

Links

JP2018530797A 2015-12-21 2016-12-15 インターロイキン−15組成物及びその使用 Withdrawn JP2019503348A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562270447P 2015-12-21 2015-12-21
US62/270,447 2015-12-21
PCT/US2016/067042 WO2017112528A2 (en) 2015-12-21 2016-12-15 Interleukin-15 compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2019503348A JP2019503348A (ja) 2019-02-07
JP2019503348A5 true JP2019503348A5 (cg-RX-API-DMAC10.html) 2020-01-30

Family

ID=59091160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018530797A Withdrawn JP2019503348A (ja) 2015-12-21 2016-12-15 インターロイキン−15組成物及びその使用

Country Status (12)

Country Link
US (1) US20180360977A1 (cg-RX-API-DMAC10.html)
EP (1) EP3393486A4 (cg-RX-API-DMAC10.html)
JP (1) JP2019503348A (cg-RX-API-DMAC10.html)
KR (1) KR20180089516A (cg-RX-API-DMAC10.html)
CN (1) CN108472324A (cg-RX-API-DMAC10.html)
AU (1) AU2016378387A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018012262A2 (cg-RX-API-DMAC10.html)
CA (1) CA3007819A1 (cg-RX-API-DMAC10.html)
IL (1) IL259919A (cg-RX-API-DMAC10.html)
MX (1) MX2018007304A (cg-RX-API-DMAC10.html)
WO (1) WO2017112528A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201803875B (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11273205B2 (en) * 2017-07-25 2022-03-15 Jiangsu Hengrui Medicine Co., Ltd. IL-15 protein complex pharmaceutical composition
AU2019224159B2 (en) * 2018-02-26 2025-05-29 Sanofi IL-15 conjugates and uses thereof
JP7097465B2 (ja) 2018-06-19 2022-07-07 アルモ・バイオサイエンシーズ・インコーポレイテッド キメラ抗原受容体細胞療法と併用するil-10剤の組成およびその使用方法
JP7611136B2 (ja) * 2018-11-09 2025-01-09 ネクター セラピューティクス 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン-15受容体作動薬
WO2020219943A1 (en) * 2019-04-26 2020-10-29 Prolynx Llc Slow-release cytokine conjugates
SG11202111409YA (en) 2019-05-20 2021-12-30 Cytune Pharma IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES
JP2022544405A (ja) * 2019-08-15 2022-10-18 アイジーエム バイオサイエンシズ インコーポレイテッド 免疫刺激性多量体型結合分子
CA3148135A1 (en) * 2019-08-23 2021-03-04 Carolina E. CAFFARO Il-15 conjugates and uses thereof
KR20230096047A (ko) 2020-10-26 2023-06-29 싸이튠 파마 비흑색종 피부암 치료용 IL-2/IL-15Rβγ 작용제
WO2022090203A1 (en) 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
JP2024526080A (ja) 2021-06-23 2024-07-17 サイチューン ファーマ インターロイキン15多様体
US20240350589A1 (en) 2021-08-13 2024-10-24 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
WO2023093826A1 (zh) * 2021-11-26 2023-06-01 杰科(天津)生物医药有限公司 一种蛋白的生产方法及其应用
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
CN117510828A (zh) * 2022-07-28 2024-02-06 厦门赛诺邦格生物科技股份有限公司 一种含氨基酸残基的三臂聚乙二醇衍生物
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2367027T3 (es) * 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
US20060057680A1 (en) * 2004-08-11 2006-03-16 Zheng Xin X Mutant interleukin-15 polypeptides
US20060104945A1 (en) * 2004-10-05 2006-05-18 Choi Yong S Enhancement of B cell proliferation by IL-15
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
EP3206713A4 (en) * 2014-10-14 2018-06-27 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof

Similar Documents

Publication Publication Date Title
Alconcel et al. FDA-approved poly (ethylene glycol)–protein conjugate drugs
US8426357B2 (en) Multimeric conjugate
Roberts et al. Chemistry for peptide and protein PEGylation
TW570802B (en) Improved interferon polymer conjugates
DK2209494T3 (en) New conjugated proteins and peptides
CN101636414B (zh) 聚乙二醇修饰的干扰素α2b及其制备方法和应用
CN1088721C (zh) 干扰素结合物
TWI364295B (en) Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
JP2016526014A5 (cg-RX-API-DMAC10.html)
US20060051315A1 (en) Polymers for delivering peptides and small molecules in vivo
JP2014516993A5 (cg-RX-API-DMAC10.html)
JP2007533665A (ja) 新規g−csf結合体
Bhawani et al. Polymer based protein therapeutics
EP2196475B1 (en) INTERFERON ALPHA 2a MODIFIED BY POLYETHYLENE GLYCOL, ITS SYNTHESIS PROCESS AND APPLICATION
JP2006521372A (ja) 生物学的活性物質と生体適合性高分子の1:1接合体、この製造方法とこれを含む薬学組成物
JP2008543304A (ja) ヒト顆粒球コロニー刺激因子イソ型(HumanGranulocyte−ColonyStimulatingFactorIsoforms)
CN1673230A (zh) 重组人复合干扰素-聚乙二醇偶联物的制备及其偶联产物
TW200426155A (en) Activated polyethylene glycol esters
CN101491682A (zh) 聚乙二醇化重组人干扰素ω偶合物及其制备工艺
KR100459105B1 (ko) 변형된 인터페론-알파 2a 및 2b, 그리고 이들과 PEG유도체와의 배합체
KR102935142B1 (ko) 멀티암형 분해성 폴리에틸렌글리콜 유도체
Bhavanasi An Expansion on Protein PEGylation for cancer therapeutics: from Bench to Bedside.
CN105017408B (zh) 聚乙二醇化血小板生成素模拟肽同源四聚体及其用途
JP2006193627A (ja) 薬物複合体および薬物送達用担体